AU2003227148A8 - Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer - Google Patents

Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer

Info

Publication number
AU2003227148A8
AU2003227148A8 AU2003227148A AU2003227148A AU2003227148A8 AU 2003227148 A8 AU2003227148 A8 AU 2003227148A8 AU 2003227148 A AU2003227148 A AU 2003227148A AU 2003227148 A AU2003227148 A AU 2003227148A AU 2003227148 A8 AU2003227148 A8 AU 2003227148A8
Authority
AU
Australia
Prior art keywords
cancer
therapeutic
monoclonal antibody
diagnostic uses
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003227148A
Other versions
AU2003227148A1 (en
Inventor
Timothy C Groves
David Young
Xiaobo Duan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arius Research Inc
Original Assignee
Arius Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arius Research Inc filed Critical Arius Research Inc
Publication of AU2003227148A8 publication Critical patent/AU2003227148A8/en
Publication of AU2003227148A1 publication Critical patent/AU2003227148A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2003227148A 2002-04-05 2003-04-07 Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer Abandoned AU2003227148A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37065902P 2002-04-05 2002-04-05
US60/370,659 2002-04-05
PCT/CA2003/000500 WO2003086456A2 (en) 2002-04-05 2003-04-07 Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer

Publications (2)

Publication Number Publication Date
AU2003227148A8 true AU2003227148A8 (en) 2003-10-27
AU2003227148A1 AU2003227148A1 (en) 2003-10-27

Family

ID=29250562

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003227148A Abandoned AU2003227148A1 (en) 2002-04-05 2003-04-07 Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer

Country Status (2)

Country Link
AU (1) AU2003227148A1 (en)
WO (1) WO2003086456A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 (en) 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7361343B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7468254B2 (en) 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7361342B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7399835B2 (en) * 2004-02-26 2008-07-15 Arius Research Inc. Cancerous disease modifying antibodies
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7456258B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7411046B2 (en) * 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7452979B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456259B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500023L (en) * 1994-05-17 1995-11-18 Beki Ab Ways to detect cancer
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
AU2003207459A1 (en) * 2002-01-03 2003-07-24 The Scripps Research Institute Cancer-associated epitope

Also Published As

Publication number Publication date
WO2003086456A2 (en) 2003-10-23
AU2003227148A1 (en) 2003-10-27
WO2003086456A3 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
TWI367102B (en) Therapeutic human anti-il-1r1 monoclonal antibody
HK1081448A1 (en) Bispecific anti-erb-b antibodies and their use in tumor therapy
PT2940044T (en) Anti-tnf alpha antibodies for use in therapy
HK1205748A1 (en) Therapeutic epitopes and uses thereof
EP1793858A4 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
IL163563A (en) Anti-amyloid beta antibodies and their use in medicine
IL172242A0 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
EP1633785A4 (en) Human monoclonal antibodies against bacillusanthracis protective antigen
IL173080A0 (en) Assay for human anti cd20 antibodies and uses therefor
EP1558284A4 (en) Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
AU2003227148A8 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
AU2003255544A8 (en) Tumor specific oligosaccharide epitopes and use thereof
EP1589033A4 (en) Antibody and use thereof
GB0326578D0 (en) Cancer diagnosis and therapy
PL371202A1 (en) Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
AU2003227861A8 (en) Protein involved in cancer
SI1639013T1 (en) Pan-kir2dl NK-receptor antibodies and their use in diagnostic and therapy
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003209459A8 (en) Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
AU2003211292A1 (en) Monoclonal antibody against human hepatoma and use thereof
EP1627888A4 (en) Antibody and use thereof
AU2003270518A8 (en) Therapeutic anti-bgp(c-cam1) antibodies and uses thereof
GB0022216D0 (en) Human FAP-a-specific antibodies for use in cancer therapy
GB0219110D0 (en) Cancer diagnosis and therapy
GB0424871D0 (en) Antibodies and their use in therapy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase